Sunshine Biopharma, Inc. (SBFM)
| Market Cap | 6.61M |
| Revenue (ttm) | 36.23M |
| Net Income (ttm) | -5.03M |
| Shares Out | 4.56M |
| EPS (ttm) | -4.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 168,500 |
| Open | 1.490 |
| Previous Close | 1.540 |
| Day's Range | 1.450 - 1.500 |
| 52-Week Range | 1.169 - 6.990 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+934.41%) |
| Earnings Date | Aug 15, 2025 |
About SBFM
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-parti... [Read more]
Financial Performance
In 2024, Sunshine Biopharma's revenue was $34.87 million, an increase of 44.75% compared to the previous year's $24.09 million. Losses were -$5.13 million, 13.9% more than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for SBFM stock is "Strong Buy" and the 12-month stock price target is $15.0.
News
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
FORT LAUDERDALE, FL / ACCESS Newswire / July 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of th...
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
FORT LAUDERDALE, FL / ACCESS Newswire / June 11, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
FORT LAUDERDALE, FL / ACCESS Newswire / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of th...
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
FORT LAUDERDALE, F / ACCESS Newswire / May 6, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ther...
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Sunshine Biopharma Inc. SBFM traded higher on Wednesday, with a session volume of 19.07 million compared to an average volume of 88.16K, according to data from Benzinga Pro.
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("We", "Our", the "Company"), a pharmaceutical company offering and researching life-saving medicines in a...
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
FORT LAUDERDALE, FL / ACCESS Newswire / March 24, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
FORT LAUDERDALE, FL / ACCESS Newswire / March 10, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic area...
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety o...
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pl...
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...
Sunshine Biopharma Launches a New Generic Prescription Drug
FORT LAUDERDALE, FL / ACCESSWIRE / December 4, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t...
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...
Sunshine Biopharma Launches Two New Generic Prescription Drugs
FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both s...
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of the...
Sunshine Biopharma Announces Reverse Stock Split
FORT LAUDERDALE, FL / ACCESSWIRE / August 6, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company offering and researching life-saving medici...
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including ...
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering an...